Results Highlight Reversal of Hyperactivity and Restoration of Associative Learning and Reduction of Anxiety, Phenotypes Associated with Fragile X Syndrome. Anavex Life Sciences Corp. (“Anavex” or

AVXL

Hershey Q2 EPS $1.80 Beats $1.68 Estimate, Sales $2.37B Beat $2.22B Estimate

By Benzinga Newsdesk

July 28, 6:47 AM

Hershey (NYSE:HSY) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.68 by 7.14 percent. This is a 22.45 percent increase over earnings of $1.47 per share from the same period

HSY

Creatd Executive Chairman Jeremy Frommer To Assume CEO Role

By Bill Haddad

September 6, 8:44 AM

Executive Chairman of the Board, Jeremy Frommer will assume the CEO seat. Creatd's board significantly amplifies its capabilities with the addition of Justin Maury, Creatd's COO and Co-founder. NEW YORK, Executive Chairman of the Board, Jeremy Frommer will assume the CEO seat.

CRTD

Mizuho Maintains Neutral on MongoDB, Raises Price Target to $300

Related Posts

Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FXS (Autism)

Hershey Q2 EPS $1.80 Beats $1.68 Estimate, Sales $2.37B Beat $2.22B Estimate

Creatd Executive Chairman Jeremy Frommer To Assume CEO Role